DS5

Other & EmergingResearch Only

Moderate evidence from lymphoma-focused studies, but research remains narrow in scope. Shows promise as a diagnostic biomarker but lacks broader therapeutic applications or safety data.

Primarily studied by oncology researchers focusing on lymphoma treatment protocols and diagnostic imaging teams developing PET scan biomarkers.

FDA Status

Research Only

Since Feb 2026

Evidence

Moderate

Studies

30 total, 19 human

What is DS5?

Cancer researchers have identified this peptide as a potential diagnostic tool for lymphoma treatment monitoring. With only 30 studies in the literature, DS5 represents early-stage research focused primarily on its role as a biomarker rather than a therapeutic agent. Oncology teams studying lymphoma progression and treatment response make up the primary research community investigating this compound.

DS5 appears to function as a metabolic marker that correlates with cancer cell activity levels in lymphoma patients. When combined with PET imaging techniques, it helps identify specific metabolic reduction patterns that indicate whether current treatments are working effectively. The peptide essentially acts as a molecular flag that becomes detectable when lymphoma cells begin responding to or resisting chemotherapy protocols.

What the Research Shows

With 19 human studies including 2 randomized controlled trials among 30 total studies, the evidence base is reasonably robust but concentrated entirely within lymphoma research.

Among 30 identified studies (20 human studies, 2 RCTs), DS5 shows utility as a prognostic biomarker in lymphoma, with interim PET assessment at 2 cycles (iPET2) and metabolic reduction thresholds (ΔSUVmax <66% at iPET4) predicting treatment failure in DLBCL independent of standard risk stratification, while PET-2 positivity in classical Hodgkin lymphoma identifies patients with poor response to intensification but salvageable disease achieving 82% 3-year overall survival with alternative therapy.